Gain insights from our experts...
Optimizing lipid nanoparticles (LNPs) processing for siRNA delivery by microfluidics system
The success of mRNA vaccines during the COVID-19 pandemic has accelerated the advancement of nucleic acid delivery technologies. In addition to mRNA, interfering RNA offers potential to treat diseases beyond the reach of small molecules. However, therapeutic success hinges on efficient and targeted delivery systems. Lipid nanoparticles (LNPs), especially those produced via microfluidics, have emerged as a leading platform for RNA delivery. delivery. for RNA.
Join Dr. Qiaobin Hu as he explores LNP formulation for siRNA delivery using a microfluidic flow-focusing system.
Optimising lipid nanoparticles (LNPs) processing for siRNA delivery by microfluidics system
866.3 KB
Explore our poster presentation with Qiaobin Hu
Explore additional content
recent insights:
Liposomal generics in Asia: Supporting scalable drug delivery through GMP lipid excellence
Across Asia, healthcare systems are balancing rising disease burden, expanding access expectations, and increasing cost pressures, making generic medicines central to national healthcare strategies
The Hidden Supply Chain Risk in Vaccines: Why Sustainably Sourced Squalene Matters
Ingredient security is no longer a background consideration for vaccine formulators and manufacturers. It is now critical high-quality ingredients are sourced from proven partners, that can provide a...
A 3rd Consecutive Win: Croda Pharma Awarded Pharma Excipients Champion and Sustainability Influencer Award at CPHI China
Croda Pharma Secures New Wins in Pharmaceutical Excipients and Sustainability